Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 known ✓ | Q9H4B7 | 10/20 | 0.63 |
| ▸ | TUBB4A known ✓ | P04350 | 9/20 | 0.63 |
| ▸ | TUBB known ✓ | P07437 | 9/20 | 0.63 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 9/20 | 0.63 |
| ▸ | TUBA1B known ✓ | P68363 | 9/20 | 0.63 |
| ▸ | TUBA4A known ✓ | P68366 | 9/20 | 0.63 |
| ▸ | TUBB4B known ✓ | P68371 | 9/20 | 0.63 |
| ▸ | TUBB3 known ✓ | Q13509 | 9/20 | 0.63 |
| ▸ | TUBB2A known ✓ | Q13885 | 9/20 | 0.63 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 9/20 | 0.63 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 9/20 | 0.63 |
| ▸ | TUBA1A known ✓ | Q71U36 | 9/20 | 0.63 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 9/20 | 0.63 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 9/20 | 0.63 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 9/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296731 | 0.89 | TUBB1 (0.64) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1508665 | 0.84 | TUBB1 (0.58) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2856230 | 0.81 | TUBB1 (0.66) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL3756295 | 0.79 | TUBB1 (0.70) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL30334938 | 0.78 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL29356562 | 0.78 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL5566666 | 0.78 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL29394501 | 0.78 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL19955 | 0.78 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL19956 | 0.78 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116287093-A | Screening method of cell-embedded death agonist or antagonist and application thereof | 无量光生物科技(鹤山市)有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-114259609-B | Support frame | 埃恩普裕(北京)科技有限公司 | 2023-02-28 | — | — | CN | claimed |
| CN-109771657-B | High-molecular antitumor drug bonded with vascular blocking agent and immunomodulator and preparation method thereof | 湘潭大学 | 2022-06-24 | — | — | CN | claimed |
| CN-114259609-A | Support frame | 宇航 | 2022-04-01 | — | — | CN | claimed |
| CN-111437396-A | Antitumor drug bonded with vascular blocking agent and immunomodulator and preparation method thereof | 成都吱吖科技有限公司 | 2020-07-24 | — | — | CN | claimed |
| CN-107550921-B | Nanoparticle-polymer injectable composite hydrogel double-drug-loading system and preparation method thereof | 南京邮电大学 | 2020-04-14 | — | — | CN | claimed |
| CN-117757052-A | Temperature-sensitive hydrogel, spray preparation, and preparation method and application thereof | 上海交通大学医学院附属瑞金医院 | 2024-03-26 | — | — | CN | disclosed |
| CN-116425670-A | Novel heterocyclic compounds as TEAD inhibitors | 英矽智能科技(上海)有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-112663057-B | Preparation method of micro-arc titanium oxide surface hydroxyapatite/carrier hydrogel composite coating | 西安交通大学 | 2023-06-27 | — | — | CN | disclosed |
| CN-116287093-A | Screening method of cell-embedded death agonist or antagonist and application thereof | 无量光生物科技(鹤山市)有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-113143854-B | Application of human serum albumin in preparation of radioactive iodine-labeled hypericin pharmaceutical preparation | 上海健康医学院 | 2023-05-12 | — | — | CN | disclosed |
| CN-114259609-B | Support frame | 埃恩普裕(北京)科技有限公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-115636842-A | Preparation method and application of oxidation-sensitive combretastatin derivative | 沈阳药科大学 | 2023-01-24 | — | — | CN | disclosed |
| CN-111925407-A | Liver-targeted modified lipid derivative and pharmaceutical formulation containing same | 苏州核鼎生物技术有限公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-109364024-B | Preparation method of targeting polymer, targeting liposome, preparation method of liposome targeting preparation and application | 潍坊医学院 | 2020-11-06 | — | — | CN | disclosed |
| CN-109364024-B | Preparation method of targeting polymer, targeting liposome, preparation method of liposome targeting preparation and application | 潍坊医学院 | 2020-11-06 | — | — | CN | disclosed |
| CN-111603436-A | Photodynamic silica nanomaterial @ hydrogel composite drug loading system, and preparation method and application thereof | 徐州医科大学 | 2020-09-01 | — | — | CN | disclosed |
| CN-111588914-A | Medicine coating for interventional or implanted medical apparatus and preparation method thereof | 辽宁垠艺生物科技股份有限公司 | 2020-08-28 | — | — | CN | disclosed |
| CN-111437396-A | Antitumor drug bonded with vascular blocking agent and immunomodulator and preparation method thereof | 成都吱吖科技有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | HDGF, F11, F12 | TUBB1 2620/4885TUBB4A 3629/4885TUBB 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.